Refractory Melanoma (DBCOND0033274)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02298959	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	Aflibercept Pembrolizumab	treatment	1	active_not_recruiting
NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	Ipilimumab Nivolumab	treatment	1 / 2	completed
NCT05039801	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	Bevacizumab Capivasertib Paclitaxel	treatment	1	recruiting
NCT05764395	Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors	Pembrolizumab Rigosertib	treatment	2	recruiting
NCT00254579	Study of CP-675,206 in Refractory Melanoma	Tremelimumab	treatment	2	completed
NCT03175432	Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases	Atezolizumab Bevacizumab Cobimetinib	treatment	2	active_not_recruiting
NCT05061017	Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)	Cyclophosphamide Nivolumab Pixatimod	treatment	2	completed
NCT04284774	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Tipifarnib	treatment	2	active_not_recruiting
NCT04093323	Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	Benzalkonium Celecoxib Interferon alfa Interferon alfa-2b Rintatolimod	treatment	2	recruiting